menu
HPAPI and Cytotoxic Drugs Manufacturing by Roots Analysis
The study also features a detailed analysis of the key drivers and trends related to this evolving domain.

Manufacturing highly potent drugproducts is technically and financially demanding; as a result, drugmanufacturers are becoming increasingly reliant on contract service providers

 

Roots Analysis is pleased toannounce the publication of its recent study, titled, “HPAPIand Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030.

 

Thereport features an extensive study of the current market landscape and futureopportunities associated with the contract manufacturing of HPAPIs andcytotoxic drugs. The study also features a detailed analysis of the key driversand trends related to this evolving domain. In addition to other elements, thestudy includes:

§  Adetailed assessment of the current market landscape of companies offeringcontract services for manufacturing HPAPIs and cytotoxic drugs.

§  Acompetitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers,featuring insightful representations.

§  Detailedprofiles of leading contract manufacturers of HPAPI and cytotoxic drugs (shortlistedon the basis of proprietary criterion).

§  Ananalysis of the partnerships that have been established in this domain, in therecent past.

§  Ananalysis of the various expansion initiatives undertaken by the players in thisdomain.

§  Anestimate of the overall, installed capacity for manufacturing HPAPIs andcytotoxic drugs based on data reported by industry stakeholders in the publicdomain.

§  Aqualitative analysis to decide whether to manufacture the potent productsin-house or engage the services of a CMO.

§  Adiscussion on affiliated trends, key drivers and challenges which are likely toimpact the industry’s evolution.

§  Acase study on the antibody drug conjugates (ADCs) manufacturing market,highlighting a list of contract service providers and in-house manufacturers inthis domain.

§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)

§  Typeof Product

§  HPAPIs

§  HighlyPotent Finished Dosage Forms

 

§ Company Size

§  Small-sized

§  Mid-sized

§  Large/ Very Large

 

§  Scaleof Operation

§  Preclinical/ Clinical

§  Commercial

 

§  Typeof Pharmacological Molecule

§  SmallMolecules

§  Biologics

 

§  Typeof Highly Potent Finished Dosage Form

§  Injectables

§  OralSolids

§  Creams

§  Others

§  Keygeographical regions

§  NorthAmerica

§  Europe

§  AsiaPacific

§  Restof the World

 

Thereport includes detailed transcripts of discussions held with the following seniorlevel representatives of stakeholder companies:

§  AntonellaMancuso (Vice President and Chief Operating Officer, BSP Pharmaceuticals) andMaria Elena Guadagno (Business Director, BSP Pharmaceuticals)

§  KlausHellerbrand (Managing Director, ProJect Pharmaceutics)

§  KevinRosenthal (Business Head, Formulations and Finished Products, Alphora Research)

§  JenniferL Mitcham (Director, Business Development, Catalent Pharma Solutions) and StacyMcDonald (Group Product Manager, Catalent Pharma Solutions)

§  RobertoMargarita (Business Development Director, CordenPharma)

§  AllisonVavala (Senior Manager, Business Development, Helsinn)

§  MarkWright (Site Head, Piramal Healthcare)

§  JavierE. Aznárez Araiz (Business Development Technician, Idifarma)

 

To request for samplereport - https://www.rootsanalysis.com/reports/299/request-sample.html

 

Keycompanies covered in the report

§ AbbVie Contract Manufacturing

§ CARBOGEN AMCIS

§ Catalent

§ Evonik

§ Formosa Laboratories

§ Intas

§ Lonza

§ MabPlex

§ Pfizer CentreOne

 

Formore information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html  

 

Other Recent Offerings

1.     Antibody ContractManufacturing Market,2020 – 2030

2.     Cell TherapyManufacturing Market(3rd Edition), 2019 – 2030

3.     Biopharma ContractManufacturing Market(3rd Edition), 2019 – 2030

 

About Roots Analysis

Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com

 

Contact Information

RootsAnalysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis